Daratumumab therapy addition improved response in systemic immunoglobulin light-chain amyloidosis
1. Daratumumab therapy addition to bortezomib, cyclophosphamide, and dexamethasone showed improved cancer response in patients with systemic immunoglobulin light-chain amyloidosis.
2. The daratumumab group presented...
Voclosporin shows clinical promise for treatment of active lupus nephritis
1. A significantly greater proportion of patients in the voclosporin group achieved complete renal responses after 52 weeks compared to the placebo group.
2. The...
Reduced-dose glucocorticoid adjunct non-inferior to high-dose glucocorticoid plus rituximab regimen for induction of disease...
1. Reduced-dose glucocorticoid plus rituximab regimen was non-inferior compared to high-dose glucocorticoid plus rituximab regimen for induction of disease remission in ANCA-associated vasculitis
Evidence Rating...
Risk factors for acute kidney injury and mortality in high risk patients undergoing cardiac...
1. In a retrospective cohort study, several pre-operative and operative factors were found to be associated with acute kidney injury and future mortality.
Evidence...
Normotensive patients with elevated cardiovascular risk may benefit from antihypertensive pharmacotherapy
1. Regardless of cardiovascular disease history and baseline blood pressure, a 5 mmHg reduction in systolic blood pressure reduced relative risk of major cardiovascular...
Routine urinary tract cancer testing among all patients with microhematuria has low diagnostic yield
1. Evaluation with cystoscopy and CT urography for patients presenting with microhematuria (MH) had a low diagnostic yield for urinary tract cancers.
2. The diagnostic...
Lumasiran decreases urinary oxalate excretion in Primary Hyperoxaluria Type 1
1. Lumasiran was shown to decrease urinary oxalate excretion in patients with Primary Hyperoxaluria Type 1.
2. Lumasiran was shown not to cause severe or...
Prediction of individuals at high risk of chronic kidney disease during treatment with lithium...
1. Individuals with bipolar disorder at higher risk of chronic kidney disease after lithium initiation include patients who are young, female, obese, have high...
Vadadustat noninferior to darbepoetin for treating anemia in dialysis patients
1. Vadadustat was shown to be non-inferior to darbepoetin alfa in cardiovascular safety for patients with anemia and dialysis-dependent chronic kidney disease (DD-CKD).
2. Vadadustat...
Postponing renal replacement therapy may result in poor clinical outcomes in patients with severe...
1. The median number of RRT-free days was 12 days (IQR 0-25) in the delayed strategy and 10 days (IQR 0-24) in the more-delayed...
